
Background British Columbia, Canada introduced clinical guidance to support the prescription of pharmaceutical alternatives to the toxic unregulated drug supply in 2020, also known as prescribed safer supply (PSS). This provincial prospective cohort study evaluates the associations between PSS receipt and self-reported health and social outcomes. Methods Data were collected in 2020–2021 using a longitudinal survey of people who had received a prescription or were seeking one (n = 161), with up to 5 time points per participant over 3 months. Generalised estimating equations were used to assess the effects of time-varying prescription exposure (yes/no) on outcomes over the follow-up period, controlling for encounters with police and bylaw officers, service use, social support, and sociodemographic characteristics. Outcomes included quality of life (EuroQOL-5D), depression (PHQ-2), anxiety (GAD-2), frequency of unregulated substance use, COVID-19 protective behaviours, and reliance on criminalized income sources. Results PSS receipt was negatively associated with depression (adj. b = -0.44, 95% CI= -0.81, -0.08) and frequency of unregulated substance use (adj. b = -0.23, 95% CI = -0.45, -0.014) over the study period. Independent of PSS receipt, there was no evidence of change in outcomes over the 12 weeks, except for a small increase in COVID-19 protective behaviours over time (adj. b = 0.004, 95% CI = 0.001, 0.007). Discussion Findings signal the potential promise of PSS, along with the need for improvement of existing service models. Further research is needed to inform the development of models that combine prescriptions with comprehensive services and supports to maximize positive outcomes.
Background The article takes a critical view of ‘a motivation model for alcohol use’ and its findings, treating young people’s substance use as a dynamic process shaped by diverse, heterogeneous forces. Methods The data consist of qualitative longitudinal interviews with young people describing their substance use practices. These practices are approached as assemblages that produce ongoing bodily lines of becoming, which can either enhance or diminish their capacities for well-being. The study identifies the diverse bodily lines of becoming produced by participants’ substance-use assemblages and analyzes how these lines, when they intersect, shape participants’ knowledge, habits, and identities related to substance use. Results The analysis shows that substance use produces multiple bodily lines, such as becoming a group; becoming strong, brave, and true to oneself; becoming happier; becoming functional, focused, and present; becoming insecure about appearance; becoming unwell, anxious, and sick; and becoming ashamed. Even if one bodily line dominates as a theme in participants’ substance use assemblages, such as becoming powerful, extroverted, or functional, the other bodily lines still exert a strong influence on how substance use practices develop, what forms they take, and what kinds of futures they open up. Conclusions Substance use is not predetermined by motives. Instead, it generates multiple bodily lines that interact in tense ways. In this landscape, the person using substances must constantly adapt to meet the challenges and demands that these lines impose on one another.
OBJECTIVES We examined the effects of state must-query prescription drug monitoring program (MQ-PDMP) and opioid prescribing limit (OPL) laws on past-year opioid misuse and opioid use disorder (OUD), in the presence and absence of legal cannabis. METHODS We used the 2015-2019 US National Survey on Drug Use and Health. We obtained policy measures from the Prescription Drug Abuse Policy System, prior literature, and statutory data. We estimated policy effects in states with and without a legal cannabis supply using two-way fixed effects models. RESULTS Relative to states without MQ-PDMP, MQ-PDMP adoption with no legal cannabis supply was associated with (non-significant) higher odds of past-year opioid misuse (AOR: 1.30; 95% CI: 1.00-1.68) and (significant) higher odds of OUD (AOR: 1.82; 95% CI: 1.09-3.03). In states with legal cannabis, MQ-PDMP adoption was associated with lower (non-significant) odds of past-year opioid misuse (AOR: 0.87; 95% CI: 0.74-1.04) and lower (non-significant) odds of OUD (AOR: 0.80; 95% CI: 0.56-1.13) compared to states without MQ-PDMP. Similar results were found for OPL and opioid misuse. OPL with legal cannabis was associated with lower (significant) odds of OUD (AOR: 0.69; 95% CI: 0.48-0.99), relative to states without an OPL. PUBLIC HEALTH IMPLICATIONS While the estimates suggest increases in opioid misuse and OUD associated with opioid prescription policies in states without legal cannabis supply, and the opposite in states with cannabis supply, imprecise estimates make it difficult to determine whether the observed patterns reflect true effects or limited precision in the policy contrasts.